| Response to the novel corona virus (COVID-19) pandemic across Africa: successes, challenges, and implications for the future OO Ogunleye, D Basu, D Mueller, J Sneddon, RA Seaton, ... Frontiers in pharmacology 11, 1205, 2020 | 207 | 2020 |
| Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries … B Godman, M Haque, J McKimm, M Abu Bakar, J Sneddon, J Wale, ... Current medical research and opinion 36 (2), 301-327, 2020 | 155 | 2020 |
| Barriers for access to new medicines: searching for the balance between rising costs and limited budgets B Godman, A Bucsics, P Vella Bonanno, W Oortwijn, CC Rothe, A Ferrario, ... Frontiers in Public Health 6, 328, 2018 | 153 | 2018 |
| Incidence, aetiology, and sequelae of viral meningitis in UK adults: a multicentre prospective observational cohort study F McGill, MJ Griffiths, LJ Bonnett, AM Geretti, BD Michael, NJ Beeching, ... The Lancet Infectious Diseases 18 (9), 992-1003, 2018 | 148 | 2018 |
| Fixed dose drug combinations–are they pharmacoeconomically sound? Findings and implications especially for lower-and middle-income countries B Godman, H McCabe, T D Leong, D Mueller, AP Martin, I Hoxha, ... Expert review of pharmacoeconomics & outcomes research 20 (1), 1-26, 2020 | 82 | 2020 |
| Rapid assessment of the potential paucity and price increases for suggested medicines and protection equipment for COVID-19 across developing countries with a particular focus … IA Sefah, OO Ogunleye, DO Essah, SA Opanga, N Butt, A Wamaitha, ... Frontiers in pharmacology 11, 588106, 2021 | 71 | 2021 |
| Payers' views of the changes arising through the possible adoption of adaptive pathways M Ermisch, A Bucsics, P Vella Bonanno, F Arickx, A Bybau, T Bochenek, ... Frontiers in pharmacology 7, 305, 2016 | 71 | 2016 |
| Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications B Godman, A Hill, S Simoens, G Selke, I Selke Krulichová, ... Expert review of pharmacoeconomics & outcomes research 21 (4), 527-540, 2021 | 66 | 2021 |
| Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future OM Atieno, S Opanga, A Martin, A Kurdi, B Godman Journal of medical economics 21 (9), 878-887, 2018 | 61 | 2018 |
| Adaptive pathways: possible next steps for payers in preparation for their potential implementation P Vella Bonanno, M Ermisch, B Godman, AP Martin, J Van Den Bergh, ... Frontiers in pharmacology 8, 497, 2017 | 53 | 2017 |
| Pricing of oral generic cancer medicines in 25 European countries; findings and implications B Godman, A Hill, S Simoens, A Kurdi, J Gulbinovič, A Martin, A Timoney, ... Generics and Biosimilars Initiative Journal 8 (2), 49-70, 2019 | 51 | 2019 |
| Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income … B Godman, C Grobler, M Van-De-Lisle, J Wale, WB Barbosa, A Massele, ... Expert opinion on pharmacotherapy 20 (18), 2237-2255, 2019 | 50 | 2019 |
| Proposal for a regulation on health technology assessment in Europe–opinions of policy makers, payers and academics from the field of HTA P Vella Bonanno, A Bucsics, S Simoens, AP Martin, W Oortwijn, ... Expert review of pharmacoeconomics & outcomes research 19 (3), 251-261, 2019 | 44 | 2019 |
| Evidence-based public policy making for medicines across countries: findings and implications for the future B Godman, J Fadare, HY Kwon, CZ Dias, A Kurdi, IP Dias Godoi, ... Journal of comparative effectiveness research 10 (12), 1019-1052, 2021 | 43 | 2021 |
| Organ preservation using contact radiotherapy for early rectal cancer: outcomes of patients treated at a single centre in the UK AS Dhadda, A Martin, S Killeen, IA Hunter Clinical Oncology 29 (3), 198-204, 2017 | 43 | 2017 |
| Time to review authorisation and funding for new cancer medicines in Europe? Inferences from the case of Olaratumab C Pontes, C Zara, J Torrent-Farnell, M Obach, C Nadal, P Vella-Bonanno, ... Applied health economics and health policy 18, 5-16, 2020 | 38 | 2020 |
| Avoiding radical surgery in elderly patients with rectal cancer is cost-effective C Rao, AS Myint, T Athanasiou, O Faiz, AP Martin, B Collins, FML Smith Diseases of the Colon & Rectum 60 (1), 30-42, 2017 | 38 | 2017 |
| Surgical trends, outcomes and disparities in minimal invasive surgery for patients with endometrial cancer in England: a retrospective cohort study EL Moss, G Morgan, AP Martin, P Sarhanis, T Ind BMJ open 10 (9), e036222, 2020 | 36 | 2020 |
| A cost analysis of haemodialysis and peritoneal dialysis for the management of end-stage renal failure at an academic hospital in Pretoria, South Africa L Makhele, M Matlala, M Sibanda, AP Martin, B Godman PharmacoEconomics-open 3, 631-641, 2019 | 35 | 2019 |
| Evidence of a disability paradox in patient‐reported outcomes in haemophilia J O’Hara, AP Martin, D Nugent, M Witkop, TW Buckner, MW Skinner, ... Haemophilia 27 (2), 245-252, 2021 | 31 | 2021 |
